Hematology Seminar is organized by American Seminar Institute (ASI).
Course(s) are appropriate for:
Family Practitioners, Pediatricians, Internists, General Practitioners, Nurses, Nurse Practitioners, and Physician Assistants (PA-C's)
Short Course: 10 AMA PRA Category 1 Credits™
Short Course Price: $485
Series 2A (HEM2A) Topics Include: Favorable and Unfavorable Cytogenetic Profiles, Platelet and Bleeding Disorders, Evaluation of Children with Anemia, Oral Anticoagulant Agents, Patients with SAH or ICH, and more.
Summarize favorable and unfavorable cytogenetic profiles observed in patients with myelodysplastic syndrome; List risks and benefits of drugs and antibodies commonly used to manage myelodysplastic syndrome; Counsel a patient with myelodysplastic syndrome who is contemplating stem cell transplantation; Weigh the risks and benefits of drugs and regimens commonly used to treat Waldenstrom macroglobulinemia; Assess the efficacy of ibrutinib for treatment of Waldenstrom macroglobulinemia.
Hematology and Oncology Review
Diagnose platelet and bleeding disorders using patient history and laboratory test results; Manage common coagulation and platelet disorders; Determine the cause of, and provide optimal treatment for, anemia; Explain the pathophysiology, clinical presentation, prognosis, and treatment of Hodgkin lymphoma and non-Hodgkin lymphoma Recognize the indications and contraindications for drugs used in the treatment of non-Hodgkin lymphoma.
Treat anemia in pediatric patients; Explain the findings associated with thrombocytopenia in pediatric patients; Identify the most common causes of neutropenia in pediatric patients; Stratify causes of anemia based on stages of pediatric development; Choose the appropriate test(s) for evaluation of children with anemia.
Update on Anticoagulation
Weigh the advantages and disadvantages of warfarin and direct-acting oral anticoagulannt agents; Recognize indications for warfarin, direct-acting oral anticoagulant agents, and low-molecular-weight heparin; Employ American College of Chest Physicians guide-lines for antithrombotic therapy; Select appropriate agents for reversal of anticoagulation; Provide effective options to patients who cannot take direct-acting oral anticoagulant agents or warfarin for anticoagulation therapy and prevention of stroke.
Qualifies for Clinical Pharmacology
Bleeding and Hemorrhage
Identify patients who require reversal of NOACs; Select optimal reversal agents based on specific NOAC and patient characteristics; Determine which patients require workup for SAH based on suggestive clinical features and history; Set adequate targets for blood pressure control in patients with SAH or ICH; Initiate critical care interventions to reduce morbidity and mortality associated with SAH and ICH.
Hematology Blood and Marrow Transplant